文献速递骨软组织肉瘤与黑色素瘤

一项全球协作研究:CIC重排、BCOR::CCNB3重排及其他超罕见未分类未分化小圆细胞肉瘤(GRACefUl)

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
PubMed 文献 · Eur J Cancer · 2023-01-18

该回顾性研究纳入1983至2019年全球21家肉瘤参考中心诊治的148例未分化小圆细胞肉瘤(URCS)患者,按分子特征分为CIC重排、BCOR::CCNB3重排和未分类三组。中位随访42.7个月,三组3年总生存率分别为39.6%、92.2%和78.7%(p<0.0001)。作者认为这是URCS最大规模研究,证实亚型间结局差异显著,怀疑URCS时应行全面分子评估。

要点

  • 148例中CIC重排88例(60%)、BCOR::CCNB3重排33例(22%)、未分类27例(18%)。
  • BCOR::CCNB3组3年OS为92.2%,CIC重排组为39.6%,未分类组为78.7%(p<0.0001)。
  • BCOR::CCNB3重排病例多见男性、年轻、骨原发且同步转移率低。

核心结论

  • 本研究是URCS最大规模研究,证实不同URCS亚型间结局存在显著差异。
  • 作者认为怀疑URCS诊断时应进行全面的分子评估。
  • 作者指出需要前瞻性研究以更好地确定各URCS亚型的最佳治疗策略。

研究设计与样本

  • 回顾性识别1983至2019年在全球21家肉瘤参考中心诊治的URCS患者。
  • 基于分子评估将病例分为CIC重排、BCOR::CCNB3重排和未分类URCS三组。
  • 共纳入148例患者,回顾其治疗、预后因素和结局。

主要发现

  • 148例中CIC重排88/148(60%),中位年龄32岁(范围7-78)。
  • BCOR::CCNB3重排33/148(22%),中位年龄17岁(范围5-91)。
  • 未分类URCS 27/148(18%),中位年龄37岁(范围4-70)。
  • 101例(68.2%)为局部病变,47例(31.8%)诊断时已有转移。
  • 中位随访42.7个月,3年OS在BCOR::CCNB3组为92.2%(95%CI 71.5-98.0),CIC重排组为39.6%(95%CI 27.7-51.3),未分类组为78.7%(95%CI 56.1-90.6),p<0.0001。

关键数值与推荐

  • 局部治疗为手术者67/148(45%),手术+放疗者52/148(35%)。
  • 接受化疗者122/148(82%)。
  • BCOR::CCNB3重排病例中观察到男性多见、年龄更小、骨原发及同步转移率低。

临床怎么用

  • 作者认为怀疑URCS诊断时应进行全面的分子评估。
  • 作者指出需要前瞻性研究以更好地确定各URCS亚型的最佳治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Undifferentiated small round cell sarcomas (URCSs) represent a diagnostic challenge, and their optimal treatment is unknown. We aimed to define the clinical characteristics, treatment, and outcome of URCS patients. METHODS: URCS patients treated from 1983 to 2019 at 21 worldwide sarcoma reference centres were retrospectively identified. Based on molecular assessment, cases were classified as follows: (1) CIC-rearranged round cell sarcomas, (2) BCOR::CCNB3-rearranged round cell sarcomas, (3) unclassified URCSs. Treatment, prognostic factors and outcome were reviewed. RESULTS: In total, 148 patients were identified [88/148 (60%) CIC-rearranged sarcoma (median age 32 years, range 7-78), 33/148 (22%) BCOR::CCNB3-rearranged (median age 17 years, range 5-91), and 27/148 (18%) unclassified URCSs (median age 37 years, range 4-70)]. One hundred-one (68.2%) cases presented with localised disease; 47 (31.8%) had metastases at diagnosis. Male prevalence, younger age, bone primary site, and a low rate of synchronous metastases were observed in BCOR::CCNB3-rearranged cases. Local treatment was surgery in 67/148 (45%) patients, and surgery + radiotherapy in 52/148 (35%). Chemotherapy was given to 122/148 (82%) patients. At a 42.7-month median follow-up, the 3-year overall survival (OS) was 92.2% (95% CI 71.5-98.0) in BCOR::CCNB3 patients, 39.6% (95% CI 27.7-51.3) in CIC-rearranged sarcomas, and 78.7% in unclassified URCSs (95% CI 56.1-90.6; p < 0.0001). CONCLUSIONS: This study is the largest conducted in URCS and confirms major differences in outcomes between URCS subtypes. A full molecular assessment should be undertaken when a diagnosis of URCS is suspected. Prospective studies are needed to better define the optimal treatment strategy in each URCS subtype.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Palmerini E, Gambarotti M, Italiano A, et al. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur J Cancer. 2023. PMID: 36791667. doi:10.1016/j.ejca.2023.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。